lesinurad

Known as: {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid 
 

Topic mentions per year

Topic mentions per year

2014-2018
0246820142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES Determine the efficacy and safety of daily lesinurad (200 or 400 mg orally) added to allopurinol in patients with… (More)
  • figure 1
  • figure 2
  • table 1
  • table 1
  • figure 3
Is this relevant?
2017
2017
OBJECTIVE To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
(+)- and (-)-Lesinurad were isolated as atropisomers from racemic lesinurad for the first time. No interconversion was observed… (More)
Is this relevant?
2016
2016
OBJECTIVES To assess the efficacy and tolerability of lesinurad, an oral selective uric acid reabsorption inhibitor, in… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2016
2016
BACKGROUND AND OBJECTIVES Lesinurad is a selective uric acid reabsorption inhibitor (SURI) under investigation for the treatment… (More)
  • table 1
  • figure 1
  • table 3
  • table 4
Is this relevant?
2016
2016
INTRODUCTION Lesinurad is a selective uric acid reabsorption inhibitor approved for the treatment of gout in combination with a… (More)
  • table 1
  • figure 1
  • table 4
  • table 3
  • figure 2
Is this relevant?
2016
2016
INTRODUCTION Lesinurad is a selective uric acid reabsorption inhibitor approved in the United States and Europe for treatment of… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Lesinurad is a selective uric acid reabsorption inhibitor under investigation for the treatment of gout. Single and multiple… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
OBJECTIVE The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?